Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALUR
stocks logo

ALUR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.95M
-47.24%
-0.630
-90.99%
3.30M
-40.86%
-0.530
-56.9%
3.70M
+9.5%
-0.420
-51.9%
Estimates Revision
The market is revising No Change the revenue expectations for Allurion Technologies Inc. (ALUR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -22.69%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-22.69%
In Past 3 Month
Wall Street analysts forecast ALUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALUR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ALUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALUR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.670
sliders
Low
6.00
Averages
6.00
High
6.00
Current: 1.670
sliders
Low
6.00
Averages
6.00
High
6.00
Chardan Capital
Keay Nakae
Hold
Maintains
$2.5
2025-03-27
Reason
Chardan Capital
Keay Nakae
Price Target
$2.5
2025-03-27
Maintains
Hold
Reason
Roth MKM
Jason Wittes
Strong Buy
Reiterates
$16
2025-03-21
Reason
Roth MKM
Jason Wittes
Price Target
$16
2025-03-21
Reiterates
Strong Buy
Reason
Chardan Capital
Keay Nakae
Hold
Maintains
$2.5
2025-03-21
Reason
Chardan Capital
Keay Nakae
Price Target
$2.5
2025-03-21
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Allurion Technologies Inc (ALUR.N) is -1.83, compared to its 5-year average forward P/E of -1.54. For a more detailed relative valuation and DCF analysis to assess Allurion Technologies Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.54
Current PE
-1.83
Overvalued PE
0.71
Undervalued PE
-3.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.21
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.89
Undervalued EV/EBITDA
-5.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.08
Current PS
0.00
Overvalued PS
5.38
Undervalued PS
-1.23
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ALUR News & Events

Events Timeline

(ET)
2025-11-25
09:30:58
Allurion announces preliminary findings on Allurion Program and tirzepatide combination.
select
2025-11-18 (ET)
2025-11-18
09:37:32
Allurion teams up with ProSurg to introduce innovative weight loss method in Brazil
select
2025-11-12 (ET)
2025-11-12
08:10:36
Allurion Technologies announces Q3 earnings per share of $1.53, below consensus estimate of $2.45.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-25Newsfilter
Allurion Achieves 23% Weight Loss with Low-Dose Tirzepatide Combination
  • Significant Weight Loss: After 12 months of treatment, 76 patients achieved an average weight loss of 23%, with lean body mass percentage increasing from 62% to 70%, demonstrating the effectiveness of the Allurion Program combined with low-dose tirzepatide, potentially setting a new treatment standard in the weight loss market.
  • High Adherence Rates: All participants adhered to tirzepatide throughout the study, indicating that the lower dosing strategy effectively reduced side effects and discontinuation rates, enhancing the long-term weight loss potential and possibly changing the usage patterns of GLP-1 medications.
  • Technological Innovation: The combination of Allurion's Smart Capsule and AI-powered Virtual Care Suite not only enhances patient treatment experiences but also optimizes weight loss outcomes through personalized monitoring and management, showcasing the company's technological leadership in the weight loss sector.
  • Future Prospects: Allurion plans to validate these initial results in future clinical trials, and if successful, this could establish its market leadership in metabolically healthy weight loss, attracting further investment and partnership opportunities.
[object Object]
Preview
4.5
11-18NASDAQ.COM
Zacks Industry Outlook Spotlights Boston Scientific, Insulet, BioLife Solutions, and Allurion

  • Industry Challenges: The medical products industry is facing significant challenges, including cost inflation from tariffs, supply-chain delays, and regulatory uncertainties, which are impacting margins and growth outlooks.

  • Resilience Through Innovation: Companies like Boston Scientific, Insulet, BioLife Solutions, and Allurion Technologies are navigating these challenges by focusing on innovation, operational efficiencies, and strategic acquisitions to drive organic growth.

  • Emerging Trends: Key trends shaping the industry include the integration of AI and digital health, a shift towards ambulatory and home-based care, advancements in robotics and specialty therapeutics, and evolving regulatory frameworks that emphasize value-based care.

  • Market Performance: The medical products industry has underperformed compared to the broader market, with a decline of 1.8% over the past year, while companies are still positioned for potential growth through strategic investments and improved operational practices.

[object Object]
Preview
9.5
08-20NASDAQ.COM
Allurion Technologies, Inc. (ALUR) Announces Q2 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Allurion Technologies, Inc. reported a quarterly loss of $0.57 per share, better than the expected loss of $0.65, but down from earnings of $0.25 per share a year ago.

  • Revenue Miss: The company generated revenues of $3.38 million for the quarter, missing estimates by 43.21% and significantly lower than $11.77 million from the previous year.

  • Stock Outlook: Allurion's shares have dropped about 78% this year, with current consensus EPS estimates indicating continued losses; the stock holds a Zacks Rank #4 (Sell), suggesting it may underperform in the near future.

  • Industry Context: The Medical - Products industry ranks in the top 39% of Zacks industries, which could influence Allurion's performance, while Agilent Technologies is set to report its results soon, with expectations of modest growth.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Allurion Technologies Inc (ALUR) stock price today?

The current price of ALUR is 1.67 USD — it has increased 0.6 % in the last trading day.

arrow icon

What is Allurion Technologies Inc (ALUR)'s business?

Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.

arrow icon

What is the price predicton of ALUR Stock?

Wall Street analysts forecast ALUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALUR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Allurion Technologies Inc (ALUR)'s revenue for the last quarter?

Allurion Technologies Inc revenue for the last quarter amounts to 2.66M USD, decreased -50.48 % YoY.

arrow icon

What is Allurion Technologies Inc (ALUR)'s earnings per share (EPS) for the last quarter?

Allurion Technologies Inc. EPS for the last quarter amounts to -1.53 USD, decreased -145.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Allurion Technologies Inc (ALUR)'s fundamentals?

The market is revising No Change the revenue expectations for Allurion Technologies Inc. (ALUR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -22.69%.
arrow icon

How many employees does Allurion Technologies Inc (ALUR). have?

Allurion Technologies Inc (ALUR) has 134 emplpoyees as of December 13 2025.

arrow icon

What is Allurion Technologies Inc (ALUR) market cap?

Today ALUR has the market capitalization of 20.59M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free